HK1132505A1 - Thiazole pyrazolopyrimidines as crf1 receptor antagonists - Google Patents

Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Info

Publication number: HK1132505A1
Authority: HK; Hong Kong
Prior art keywords: receptor antagonists; crf1 receptor; pyrazolopyrimidines; thiazole; thiazole pyrazolopyrimidines
Prior art date: 2006-09-20

Application number

HK10100143.4A

Other languages

English (en)

Inventor

Zhaogen Chen

Chafiq Hamdouchi Hamdouchi

Erik James Hembre

Philip Arthur Hipskind

Jason Kenneth Myers

Takako Takakuwa

James Lee Toth

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2010-01-08

Publication date

2010-02-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1132505(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-01-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-02-26 Publication of HK1132505A1 publication Critical patent/HK1132505A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HK10100143.4A 2006-09-20 2010-01-08 Thiazole pyrazolopyrimidines as crf1 receptor antagonists HK1132505A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (en)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Publications (1)

Publication Number	Publication Date
HK1132505A1 true HK1132505A1 (en)	2010-02-26

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK10100143.4A HK1132505A1 (en)	2006-09-20	2010-01-08	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Country Status (34)

Country	Link
US (1)	US8030304B2 (de)
EP (1)	EP2094709B1 (de)
JP (1)	JP5161226B2 (de)
KR (1)	KR101088239B1 (de)
CN (1)	CN101516887B (de)
AR (1)	AR062886A1 (de)
AT (1)	ATE481405T1 (de)
AU (1)	AU2007297421B2 (de)
BR (1)	BRPI0717023B8 (de)
CA (1)	CA2663511C (de)
CL (1)	CL2007002693A1 (de)
CR (1)	CR10682A (de)
CY (1)	CY1110854T1 (de)
DE (1)	DE602007009305D1 (de)
DK (1)	DK2094709T3 (de)
EA (1)	EA015179B1 (de)
ES (1)	ES2350282T3 (de)
HK (1)	HK1132505A1 (de)
HR (1)	HRP20100516T1 (de)
IL (1)	IL197614A (de)
MA (1)	MA30798B1 (de)
MX (1)	MX2009003125A (de)
MY (1)	MY146388A (de)
NO (1)	NO20091489L (de)
NZ (1)	NZ575572A (de)
PE (1)	PE20081377A1 (de)
PL (1)	PL2094709T3 (de)
PT (1)	PT2094709E (de)
RS (1)	RS51545B (de)
SI (1)	SI2094709T1 (de)
TN (1)	TN2009000095A1 (de)
TW (1)	TWI402269B (de)
UA (1)	UA96458C2 (de)
WO (1)	WO2008036579A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0920838A2 (pt) *	2008-10-02	2018-10-16	Lilly Co Eli	composto de tiazolil-pirazolopirimidina como intermediários sintéticos e processos sintéticos relacionados
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
US20170020877A1 (en) *	2014-01-21	2017-01-26	Neurocrine Biosciences, Inc.	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
KR102571296B1 (ko)	2016-09-07	2023-08-28	더 리전트 오브 더 유니버시티 오브 캘리포니아	P-tau를 감소시키고 인지를 개선하는 알로스테릭 코르티코트로핀-방출 인자 수용체 1 (crfr1) 길항제
BR112020002967A2 (pt) *	2017-08-14	2020-08-11	Spruce Biosciences, Inc.	antagonistas de receptor de fator de liberação de corticotropina
EA202090321A1 (ru) *	2017-08-14	2020-09-24	Спрюс Биосайнсес, Инк.	Антагонисты рецептора кортикотропин-рилизинг фактора
MX2020011344A (es)	2018-04-27	2021-02-09	Spruce Biosciences Inc	Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
AU2019393256A1 (en)	2018-12-07	2021-07-29	Neurocrine Biosciences, Inc.	CRF1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX2022000812A (es) *	2019-07-19	2022-02-16	Spruce Biosciences Inc	Metodos de tratamiento de hiperplasia suprarrenal congenita.
US20230065034A1 (en) *	2019-12-04	2023-03-02	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
BR112023002497A2 (pt) *	2020-08-12	2023-05-02	Spruce Biosciences Inc	Métodos e composições para tratamento da síndrome dos ovários policísticos
JP2023540223A (ja)	2020-08-26	2023-09-22	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
JP2024539907A (ja) *	2021-11-19	2024-10-31	スプルースバイオサイエンシーズ，インク．	チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69323768T2 (de)	1992-12-17	1999-07-01	Pfizer Inc., New York, N.Y.	Pyrrolopyrimidine als crf antagonisten
CN1090189C (zh)	1996-02-07	2002-09-04	詹森药业有限公司	吡唑并嘧啶类化合物
EP0915880B1 (de) *	1996-07-24	2007-10-10	Bristol-Myers Squibb Pharma Company	Azolotriazine und pyrimidine
NZ333777A (en) *	1996-07-24	2000-07-28	Du Pont Pharm Co	(1,5-a) pyrazolo and triazole triazines and pyrimidines
IL127566A0 (en)	1996-08-28	1999-10-28	Pfizer	Substituted 6,5-hetero- bicyclic derivatives
EP1040831A3 (de) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Verwendung von Corticotropin Releasing Factor (CRF) Antagonisten zur Prophylaxe des plötzlichen Todes
WO2000059908A2 (en)	1999-04-06	2000-10-12	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
EP1218381B1 (de)	1999-09-30	2006-12-06	Neurogen Corporation	Amino-substituierte pyrazolo¬1,5-a\|-1,5-pyrimidine und pyrazolo¬1,5-a\|-1,3,5-triazine
CA2440553C (en) *	2001-03-13	2010-06-08	Paul J. Gilligan	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
WO2005063755A1 (en)	2003-12-22	2005-07-14	Sb Pharmco Puerto Rico Inc	Crf receptor antagonists and methods relating thereto

2007
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/en active Application Filing
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active IP Right Cessation
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 CA CA2663511A patent/CA2663511C/en active Active
- 2007-09-17 EP EP07842582A patent/EP2094709B1/de active Active
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
2010
- 2010-01-08 HK HK10100143.4A patent/HK1132505A1/xx active IP Right Revival
- 2010-09-21 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
CN101516887B (zh)	2011-11-02
NO20091489L (no)	2009-04-16
CY1110854T1 (el)	2015-06-10
CR10682A (es)	2009-08-13
PL2094709T3 (pl)	2011-02-28
ATE481405T1 (de)	2010-10-15
JP2010504344A (ja)	2010-02-12
AU2007297421A1 (en)	2008-03-27
SI2094709T1 (sl)	2011-01-31
BRPI0717023B1 (pt)	2019-11-19
BRPI0717023B8 (pt)	2021-05-25
UA96458C2 (ru)	2011-11-10
BRPI0717023A2 (pt)	2014-03-11
RS51545B (en)	2011-06-30
EA015179B1 (ru)	2011-06-30
NZ575572A (en)	2011-10-28
CN101516887A (zh)	2009-08-26
DK2094709T3 (da)	2010-12-06
HRP20100516T1 (hr)	2010-10-31
CA2663511A1 (en)	2008-03-27
CA2663511C (en)	2012-12-04
KR20090052366A (ko)	2009-05-25
TWI402269B (zh)	2013-07-21
IL197614A0 (en)	2009-12-24
WO2008036579A1 (en)	2008-03-27
EA200970303A1 (ru)	2009-10-30
PT2094709E (pt)	2010-10-04
TW200821312A (en)	2008-05-16
AR062886A1 (es)	2008-12-10
AU2007297421B2 (en)	2012-03-08
US8030304B2 (en)	2011-10-04
EP2094709B1 (de)	2010-09-15
ES2350282T3 (es)	2011-01-20
EP2094709A1 (de)	2009-09-02
MA30798B1 (fr)	2009-10-01
MY146388A (en)	2012-08-15
PE20081377A1 (es)	2008-09-18
MX2009003125A (es)	2009-05-28
US20100222339A1 (en)	2010-09-02
KR101088239B1 (ko)	2011-11-30
DE602007009305D1 (de)	2010-10-28
IL197614A (en)	2012-10-31
CL2007002693A1 (es)	2008-04-18
JP5161226B2 (ja)	2013-03-13
TN2009000095A1 (en)	2010-08-19

Publication	Publication Date	Title
HK1132505A1 (en)	2010-02-26	Thiazole pyrazolopyrimidines as crf1 receptor antagonists
PL2004654T3 (pl)	2013-12-31	Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy
IL226486A (en)	2015-11-30	Converted pyrazolopyrimidine compounds
IL201112A0 (en)	2010-05-17	Thiazolidine derivatives as orexin receptor antagonists
IL194583A0 (en)	2009-08-03	Imidazo compounds
EP2099454A4 (de)	2010-11-10	Aminopyrrolidine als chemokinrezeptor-antagonisten
IL185692A0 (en)	2008-01-06	Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
EP2079467A4 (de)	2010-12-15	Antidiabetische bicyclische verbindungen
ZA201002334B (en)	2011-03-30	Imidazo
ZA200706353B (en)	2009-09-30	Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
EP2093337A4 (de)	2013-09-11	Mehrzweckteil
ZA200901124B (en)	2010-05-26	Quinuclidine derivatives as M3 antagonists
EP2054434A4 (de)	2011-07-13	Myostatin-antagonisten
IL201165A0 (en)	2010-05-17	CRIg ANTAGONISTS
PL2069310T3 (pl)	2012-05-31	Pochodne sulfonylopirazolino-1-karboksyamidyny jako antagoniści 5-HT6
IL211030A0 (en)	2011-04-28	Pyrazolo [5,1-b] oxazole derivatives as crf1 antagonists
SI2004654T1 (sl)	2013-11-29	Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
GB0613737D0 (en)	2006-08-23	Retroreflector
IL202339A0 (en)	2010-06-30	Azacyclylbenzamide derivatives as histamine-3 antagonists
GB0612063D0 (en)	2006-07-26	Railing
GB201000798D0 (en)	2010-03-03	Poly-TLR antagonists
HK1129105A1 (en)	2009-11-20	Pyrazolo
GB0611451D0 (en)	2006-07-19	Cellular antagonist
GB0724654D0 (en)	2008-01-30	Prolactin antagonist
EP2139329A4 (de)	2010-04-21	Neuartige imidazo-basierte heterozyklen

Legal Events

Date	Code	Title	Description
2016-04-15	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20150917
2016-08-19	ARF	Application filed for restoration	Effective date: 20160622